Advertisement
The Body: The Complete HIV/AIDS Resource Follow Us Follow Us on Facebook Follow Us on Twitter Download Our App
Professionals >> Visit The Body PROThe Body en Espanol
HIV/AIDS Blog Central

Looking Forward to a Bright New Year in HIV/HCV Treatment

By Barbara McGovern, M.D.

January 10, 2012

As we discover a sense of renewal with the beginning of 2012, I find myself more hopeful than I have ever been regarding the outlook for patients with hepatitis C virus (HCV) infection, including patients coinfected with HIV.

Over the years, we have been aware that treatment responses have been lower in HIV/HCV coinfected patients compared to those with HCV alone. This has been particularly true of those who had an HCV genotype 1 infection, where response rates have ranged from 25 to 35 percent with pegylated interferon and ribavirin. It has also been discouraging to see patients experience significant side effects with these two medications over months of treatment, only to see their virus rebound after treatment is stopped. I have seen many brave patients continue on despite severe fatigue, nausea, loss of appetite, weight loss and other side effects because they so desperately wanted to be cured of their HCV infection.

Well, I believe it is time to ring a bell of joy because so much progress is being made in the field of HCV therapy. The results of two major trials in HCV-infected patients have led to the approval of two new drugs, telaprevir and boceprevir, in the U.S. and Europe. Both of these drugs are HCV "protease inhibitors." These trials demonstrated that "triple therapy" including pegylated interferon and ribavirin plus a HCV protease inhibitor were much more effective than dual therapy.

Advertisement
This will also be a landmark year because we will see the final results of two trials of triple therapy in HIV/HCV coinfected patients. Both trials are using pegylated interferon plus ribavirin plus a specific HCV protease inhibitor. In one trial the protease inhibitor is telaprevir and in the other it is boceprevir. Drug interactions are being studied carefully as well, because of concerns about interactions with HIV medications. So far, the results are looking good with the specific HIV medications that have been chosen for use in the trial.

And triple therapy is just the beginning. Multiple other drug classes for HCV are being developed including HCV polymerase inhibitors, NS5A inhibitors and other drug classes as well. There are even trials of combination therapy without pegylated interferon. Cure rates without interferon are very encouraging, although we must keep in mind that we are still a few years away from getting any of these drugs in the clinic. Larger trials will also need to demonstrate ongoing safety and efficacy in greater numbers of patients.

Most of these new drugs target different parts of the life cycle of the virus so they are specific for HCV. This is just like all the drug classes for HIV: We have nucleoside analog reverse transcriptase inhibitors, protease inhibitors and many other classes of drugs. When you combine them and target the virus in various stages of growth, you can stop the virus right in its tracks. This approach has led to high rates of viral suppression of HIV. A similar approach with HCV promises not only to suppress the virus, but to eradicate it completely.

So let's go for the cure in 2012. I will be discussing the 24-week results of each trial in future blogs. The preliminary results look very encouraging! Stay tuned!!

With best wishes for a happy new year and a healthy liver!

If you have questions about treating HIV/hepatitis C coinfection, Dr. McGovern is available to answer them! Visit our "Ask the Experts" forum on Hepatitis & HIV Coinfection to ask Dr. McGovern your question or browse her archive of answers.

Get email notifications every time this blog is updated.

See Also
Talk to a Physician About HIV/Hepatitis Coinfection in Our "Ask the Experts" Forums
More News on Hepatitis C Treatment
Advertisement:
Find out how a Walgreens specially trained pharmacist can help you

No comments have been made.
 

Add Your Comment:
(Please note: Your name and comment will be public, and may even show up in
Internet search results. Be careful when providing personal information! Before
adding your comment, please read TheBody.com's Comment Policy.)

Your Name:


Your Location:

(ex: San Francisco, CA)

Your Comment:

Characters remaining:
BLOG:
Making Progress on HCV Treatment in HIV-Infected Patients


Barbara McGovern, M.D., is an associate professor of medicine at the Tufts University School of Medicine and an attending physician in the Division of Infectious Diseases at Lemuel Shattuck Hospital in Boston. She is a widely published researcher and frequent lecturer on issues pertaining to HIV and coinfections with hepatitis B and hepatitis C. More information about Dr. McGovern is available on her bio page.


Subscribe to Barbara's Blog:

Subscribe by RSSBy RSS ?

Subscribe by Email


Recent Posts:


View All Posts


A Brief Disclaimer:

The opinions expressed by TheBody.com's bloggers are entirely their own, and do not necessarily reflect the views of TheBody.com itself.

Advertisement